Two First-In-Class, Clinical-Stage Antibodies
Leap Therapeutics’ lead clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK-1) protein, and is currently being studied in clinical trials in esophageal cancer and cholangiocarcinoma, a form of bile duct cancer. Our lead indication, esophageal cancer, is an aggressive disease with 17,000 patients diagnosed annually in the US and 400,000 diagnosed worldwide. More than 50% of patients present with advanced disease, with an expected survival of only 8-12 months. There are no approved therapies for relapsed or refractory disease of the esophagus.
On June 3, 2017, Leap presented data from its ongoing biliary tract cancer trial at the ASCO Annual Meeting. Click here to view our poster.
On January 19, 2017, Leap presented biomarker and efficacy data from its ongoing esophageal cancer trial at the ASCO GI meeting. Click here to view our poster.
On April 2, 2017, Leap presented non-clinical and clinical data at the AACR Annual Meeting. Click here to view our poster.
Leap Therapeutics’ second clinical candidate, TRX518, is a novel, humanized anti-GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody designed to enhance the immune system’s anti-tumor response as an immune checkpoint agonist. TRX518 is currently in Phase 1 clinical trials in solid tumor malignancies. On June 5th, 2016, Leap presented early data from its single dose, dose escalation study in solid tumors at the ASCO Annual Meeting. Click here to view our poster.